促性腺激素释放激素类似物联合重组人生长激素对中枢性性早熟女童身高的影响

王春林; 梁黎; 留佩宁; 金献江; 陈临琪; 杨凡; 连群; 陈瑞敏

doi:10.7499/j.issn.1008-8830.2014.01.006

PDF(1343 KB)

HTML

中国当代儿科杂志 ›› 2014, Vol. 16 ›› Issue (1) : 25-30. DOI: 10.7499/j.issn.1008-8830.2014.01.006

论著·临床研究

促性腺激素释放激素类似物联合重组人生长激素对中枢性性早熟女童身高的影响

王春林¹, 梁黎¹, 留佩宁², 金献江², 陈临琪³, 杨凡⁴, 连群⁵, 陈瑞敏⁶

作者信息 +

Effects of gonadotropin releasing hormone analog and growth hormone on height in girls with idiopathic central precocious puberty

WANG Chun-Lin¹, LIANG Li¹, LIU Pei-Ning², JIN Xian-Jiang², CHEN Lin-Qi³, YANG Fang⁴, LIAN Qun⁵, CHEN Rui-Min⁶

Author information +

文章历史 +

摘要

目的研究促性腺激素释放激素类似物（GnRHa）与重组人生长激素（rhGh）联合治疗以及GnRHa单用对骨龄≥10岁的特发性中枢性性早熟（ICPP）女童成年身高的改善情况。方法将6个医学中心确诊为ICPP符合研究条件的80例女童（年龄9.0±0.7岁，骨龄≥10岁）根据治疗方法分为GnRHa与rhGh联合治疗组（31例）及GnRHa单用组（49例）。观察治疗前后的预测成年身高、接近成年身高和身高净获等各项指标的变化。结果两组在治疗后按骨龄的身高标准差分值均较治疗前有显著改善（P<0.01），其中GnRHa与rhGh联合治疗组明显优于GnRHa单用组（P<0.01）。联合用药组接近成年身高（157±6 cm vs 157±4 cm）、身高净获（4.68 cm vs 3.89 cm）、停药时预测成年身高（161±5 cm vs 158±5 cm）、接近成年身高与遗传靶身高差值等指标均略高于GnRHa单用组，但差异无统计学意义（均P >0.05）。结论 GnRHa与rhGh联合治疗或GnRHa单用组均能改善骨龄≥10岁ICCP女童的成年身高，但两药联用优势不明显。对ICPP患儿预测成年身高的评估需要慎重，停药时的预测值偏高。

Abstract

Objective To determine the effect of gonadotropin releasing hormone agonist (GnRHa), by itself alone or in combination with recombinant human growth hormone (rhGH), on height in young girls (bone age≥10 years) with idiopathic central precocious puberty (ICPP). Methods Eighty girls with ICPP (9.0±0.7 years old) from six medical centers across Southeast and Southwest China participated in this study. They were allocated to treatment with GnRHa+rhGH (n=31) and GnRHa (n=49) respectively. Girls in the GnRHa+rhGH group (bone age 11.18±0.53 years) were treated with GnRHa for 25.29±6.92 months and rhGH for 12.87±7.02 months. Girls in the GnRHa group (bone age 11.03±0.50 years) were treated with GnRHa for 25.96±8.95 months. The height standard deviation for bone age (HtSDS-BA), predicted adult height, near-adult height and net height increase before and after treatment were recorded for girls in both groups. Results HtSDS-BA was significantly improved after treatment for both groups (P<0.01) and the HtSDS-BA value was superior in the GnRHa+rhGH group over the GnRHa group (P<0.01). Values in near adult height (157±6 cm vs 157±4 cm), net height increase after treatment (4.68 cm vs 3.89 cm), and predicted adult height after drug withdrawal (161±5 cm vs 158±5 cm) were higher in the GnRHa+rhGH group than the GnRHa group, but the differences were not significant. Conclusions Both GnRHa plus rhGH and GnRHa alone can improve the near adult height in girls with ICPP with a bone age ≥10 years to a similar extent. Adult height predicted based on bone age in ICPP girls following drug withdrawal is usually overestimated and precautions should be taken when this parameter is used.

导出引用

王春林, 梁黎, 留佩宁, 金献江, 陈临琪, 杨凡, 连群, 陈瑞敏. 促性腺激素释放激素类似物联合重组人生长激素对中枢性性早熟女童身高的影响[J]. 中国当代儿科杂志. 2014, 16(1): 25-30 https://doi.org/10.7499/j.issn.1008-8830.2014.01.006

WANG Chun-Lin, LIANG Li, LIU Pei-Ning, JIN Xian-Jiang, CHEN Lin-Qi, YANG Fang, LIAN Qun, CHEN Rui-Min. Effects of gonadotropin releasing hormone analog and growth hormone on height in girls with idiopathic central precocious puberty[J]. Chinese Journal of Contemporary Pediatrics. 2014, 16(1): 25-30 https://doi.org/10.7499/j.issn.1008-8830.2014.01.006

参考文献

[1] Lazar L, Padoa A, Philip M. Growth pattern and final height after cessation of gonadotropin-suppressive therapy in girls with central sexual precocity [J]. J Clin Endocrinol Metab, 2007, 92(9): 3483-3492.
[2] 李筠,梁黎,孙莉颖,等. 联合应用促性腺激素类似物和生长激素治疗女性初潮后特发性中枢性性早熟[J]. 中华儿科杂志, 2005, 43(8): 627-628.
[3] 杜俊君, 赵凯, 阮莉莉, 等. 促性腺激素释放素类似物联合人重组生长激素治疗青春期特发性矮小女童[J]. 中外医疗, 2009, 28(33): 68-69.
[4] 中华医学会儿科学分会内分泌遗传代谢学组. 中枢性(真性)性早熟诊治指南[J]. 中华儿科杂志, 2007, 45(6): 426-427.
[5] 刘箐华, 田国力, 许洪平, 等. 简易化黄体生成素释放激素激发试验诊断性早熟[J]. 实用儿科临床杂志, 2007, 22(8): 593-594.
[6] 李辉, 季成叶, 宗心南, 等. 中国0~18岁儿童、青少年身高、体重的标准化生长曲线[J]. 中华儿科杂志, 2009, 47(7): 487-492.
[7] 梁黎, 傅君芬. 儿童肥胖与代谢综合征[M]. 北京:人民卫生出版社, 2012: 10.
[8] 陈雪峰, 梁黎, 傅君芬, 等. 中国儿童青少年形体学测量指数调查[J]. 中华流行病学杂志, 2012, 33(5): 449-545.
[9] Kamp, GA, Mul D, Waelkens JJ, et al. A randomized controlled trial of Three years growth hormone and conadotropin-releasing hormone agonist treatment in children with idiopathic short stature and intrauterine growth retardation[J]. J Clin Endocrinol Metab, 2001, 28(7): 2969-2975.
[10] van Gool SA, Kamp GA, Visser-van Balen H, et al. Final height outcome after three years of growth hormone and gonadotropin-releasing hormone agonist treatment in short adolescents with relatively early puberty[J]. J Clin Endocrinol Metab, 2007, 92(4): 1402-1408.
[11] Lanes R, Gunczler P. Final height after combined growth hormone and gonadotrophin-releasing hormone analogue therapy in short healthy children entering into normally timed puberty[J]. Clin Endocrinol (Oxf), 1998, 49(2): 197-202.
[12] Lem AJ, van der Kaay DC, de Ridder MA, et al. Adult height in short children born SGA treated with growth hormone and gonadotropin releasing hormone analog: results of a randomized, dose-response GH trial[J]. J Clin Endocrinol Metab, 2012, 97(11): 4096-4105.